Clephedrone

# Research Output: Clephedrone (4-CMC)

**Substance:** Clephedrone (4-chloromethcathinone, 4-CMC)
**PSX ID:** PSX-0416
**Research Date:** 2026-05-08
**Readiness Classification:** Sparse/Emerging (first human study published 2025)

---

## Chemical Identity

**IUPAC name:** 1-(4-chlorophenyl)-2-(methylamino)propan-1-one [Ref 17]
**Molecular formula:** C₁₀H₁₂ClNO [Ref 1 — PubChem CID 82100418]
**Molecular weight:** 197.66 g/mol [Ref 1]
**InChIKey:** UEJBEYOXRNGPEI-UHFFFAOYSA-N [Ref 1]
**SMILES:** CNC(C)C(=O)c1ccc(Cl)cc1 (derived from IUPAC structure; consistent with PubChem entry)
**PubChem CID:** 82100418 [Ref 1]
**CAS numbers:** Free base: 1225843-86-6; Hydrochloride salt: 2319878-22-1 [web_retrieved — Cayman Chemical product listings]

**Seed data verification:** The brief contains no SMILES, formula, weight, or InChIKey — all confirmed from PubChem. PubChem CID (82100418) not in brief; now verified. No discrepancies with seed data because seed chemical fields were blank.

**Stereochemistry:** Clephedrone contains one chiral center at the α-carbon, making it a racemic compound. Taschwer et al. (2014 [Ref 17]) first characterized a commercially available sample as a racemic mixture and developed enantioselective GC and CE methods for chiral separation. Jorbenadze et al. (2024 [Ref 13]) confirmed ongoing challenges in developing validated enantioselective analytical methods, including instability of enantiomers in biological matrices and lack of commercially available enantiomerically pure standards with confirmed absolute stereochemistry. The pharmacologically active isomer(s) have not been identified in published literature. ⚠️ FLAG: Active isomer unknown — safety-critical gap.

**Physical form:** White crystalline powder in commercially acquired samples (Taschwer et al. 2014 [Ref 17]).

**Synthesis route:** Chloromethcathinones are commonly synthesized from chloropropiophenone via α-bromination followed by methylamine displacement (nucleophilic substitution) [web_retrieved — multiple synthetic chemistry sources]. No peer-reviewed synthesis paper specifically for 4-CMC is available in literature.

---

## Pharmacology

### Mechanism of Action

Clephedrone is a non-selective triple monoamine releasing agent acting primarily at the dopamine transporter (DAT), norepinephrine transporter (NET), and serotonin transporter (SERT). Chojnacki et al. (2023 [Ref 2]) characterized the transporter pharmacology of 4-CMC in rat synaptosomes using both uptake inhibition and substrate release assays, providing the definitive quantitative dataset.

### Transporter Potency (Chojnacki et al. 2023 [Ref 2])

| Transporter | Function | EC50/IC50 (nM) | Emax (%) |
|-------------|----------|----------------|----------|
| DAT | Uptake inhibition | 1014 ± 78 | — |
| DAT | Release (substrate) | 91 ± 11 | 109 |
| NET | Uptake inhibition | 559 ± 57 | — |
| NET | Release (substrate) | 99 ± 18 | 102 |
| SERT | Uptake inhibition | 542 ± 38 | — |
| SERT | Release (substrate) | 169 ± 20 | 109 |

**Mephedrone comparison (same study [Ref 2]):**
- DAT release: EC50 = 103 ± 16 nM (Emax 114%)
- NET release: EC50 = 83 ± 20 nM (Emax 100%)
- SERT release: EC50 = 188 ± 22 nM (Emax 108%)

4-CMC and mephedrone show virtually identical potency across all three transporters. Both function as full substrates (releasers) at DAT, NET, and SERT, consistent with an MDMA-type non-selective monoamine releasing mechanism [Ref 2]. The DAT/SERT release potency ratio for 4-CMC is approximately 1.85:1, indicating modest dopamine-over-serotonin selectivity. Negus & Banks (2017 [Ref 27]) established in a QSAR framework that high DAT/SERT potency ratios correlate with high abuse potential in 4-substituted methcathinone analogs; 4-CMC falls in an intermediate range.

**Mechanistic note:** 4-CMC does NOT appear to be a TAAR1 (trace amine-associated receptor 1) ligand — this is a class property of cathinones (Simmler et al. 2012 [Ref 31]), in contrast to non-β-keto amphetamines. The cardiovascular effects of 4-CMC are mediated through α1-adrenergic signaling (blood pressure) and D1 dopaminergic signaling (locomotion/tachycardia), confirmed by antagonist studies in rats (Chojnacki et al. 2023 [Ref 2]).

### In Vivo Neurochemical and Cardiovascular Effects

In rats implanted with telemetry transmitters, Chojnacki et al. (2023 [Ref 2]) found that 4-CMC (doses 1, 3, 10 mg/kg i.p.) produced:
- **Blood pressure:** Significant elevation comparable to mephedrone at 10 mg/kg
- **Heart rate:** Significant elevation at 3 mg/kg and 10 mg/kg; comparable to mephedrone
- **Locomotor activity:** Significant dose-dependent increase
- **Body temperature:** Transient decrease of approximately 1°C at 10 mg/kg (hypothermic at high doses, contrasting with some other cathinones)

Wojcieszak et al. (2020 [Ref 7]) confirmed dose-dependent horizontal locomotor stimulation in mice, with 3-CMC and 4-CMC both stimulating locomotor activity in a pattern consistent with monoamine releasing agents (enhanced horizontal but not vertical locomotion, contrasting with dopamine-selective cathinones).

### Receptor Binding

No published binding affinity data (Ki values) at monoamine receptors beyond transporter assays (DAT, NET, SERT). No data on 5-HT2A, D1, D2, α-adrenergic, or other receptor binding affinities for 4-CMC specifically. ⚠️ FLAG: Receptor binding profile (beyond transporters) is absent from published literature.

---

## Pharmacokinetics

### Routes of Administration and Bioavailability

Published human pharmacokinetic data exist for:
- **Oral administration:** 100 mg or 150 mg doses in controlled observation studies (Poyatos et al. 2025 [Ref 1]; Massano et al. 2024 [Ref 5]; Núñez-Montero et al. 2023 [Ref 6])
- **Intranasal administration:** Not directly studied for 4-CMC specifically (available intranasal data are from NEP/NEH, not 4-CMC, in Massano 2024 [Ref 5] and Núñez-Montero 2023 [Ref 6])

No published bioavailability (F%) data for any route.

### Oral Pharmacokinetic Profile

Poyatos et al. (2025 [Ref 1]) conducted the only controlled human study of clephedrone pharmacological effects: 8 healthy volunteers (6 women) self-administered a single oral dose (100 or 150 mg), with oral fluid sampling and vital sign monitoring over 5 hours. Key findings:
- **Delayed onset** compared to methylone under similar conditions
- **Peak oral fluid concentration** reached later than methylone, consistent with delayed pharmacodynamic effects
- Effects were stimulant-like and observable within the 5-hour monitoring window

Núñez-Montero et al. (2023 [Ref 6]) found that after 100 mg oral administration, 4-CMC reached its **maximum oral fluid concentration in the first 3 hours** — substantially later than intranasally administered cathinones (NEP and NEH), which peaked within the first hour.

Massano et al. (2024 [Ref 5]) found that 4-CMC was **detected at high concentrations in its original (unchanged) form even 5 hours after oral administration**, attributed to its **long half-life and low intrinsic clearance** compared to other synthetic cathinones.

Lopes et al. (2023 [Ref 19]) formally classified 4-CMC as a **low-clearance compound** in a pharmacokinetic profiling study using human hepatocyte incubation — in contrast to most other cathinones in the study, which were classified as intermediate clearance. This is a clinically significant distinction: low clearance compounds accumulate with repeated dosing and have longer detection windows.

**Sweat excretion:** Approximately 0.3% of the orally administered dose was recovered in sweat over 4 hours (Núñez-Montero et al. 2023 [Ref 6]).

⚠️ FLAG: No human half-life (t½), Cmax, Tmax, or Vd values are available in published literature. The above data are observational/descriptive from small pilot studies.

### Metabolism

Berardinelli et al. (2024 [Ref 4]) conducted the most comprehensive human metabolic profiling of 4-CMC using human hepatocyte incubation combined with LC-HRMS/MS, validated against clinical/forensic samples. Ten metabolites were identified.

**Primary metabolic reactions:**
1. **Ketoreduction** (keto group reduction to alcohol) — major Phase I pathway
2. **N-demethylation** — major Phase I pathway
3. **Novel pathway (previously unreported for methcathinone analogues):** Combination of β-ketoreduction + oxidative deamination + O-glucuronidation → **main metabolite in 4-CMC-positive urine samples**
   - Critical note: this metabolite is detectable only in **negative-ionization mode** and is not detectable after glucuronide hydrolysis — meaning standard positive-ion screening will miss it

Massano et al. (2024 [Ref 5]) confirmed Phase I metabolites (keto reduction, hydroxylation, dealkylation) and identified 4-CMC-glucuronide as a relevant Phase II metabolite in urine.

Lopes et al. (2023 [Ref 19]) identified keto group reduction and hydroxylation as common metabolic pathways; glucuronic acid conjugation to ketoreduced metabolites as the sole Phase II transformation.

**Biomarker for CMC intake:** Romańczuk et al. (2023 [Ref 18]) demonstrated that **dihydro-CMC** (the ketoreduced metabolite) is a more stable biomarker of intake than the parent drug in postmortem biological samples. In a series of 27 deaths, dihydro-CMC was detected in blood even when the parent compound was absent due to degradation.

**Stability issues:** 4-CMC is **particularly unstable** in biological matrices, especially at room temperature and even at +4°C over extended periods. Adamowicz & Malczyk (2019 [Ref 25]) documented this instability in blood and urine. Nowak et al. (2021 [Ref 20]) confirmed that 4-CMC and 4-CIC were the least stable substances in their study after 775 days at +4°C. This instability creates significant challenges for forensic interpretation. ⚠️ FLAG: Forensic concentrations in postmortem samples may underestimate actual exposure.

**CYP enzyme involvement:** No published data for 4-CMC specifically. This is a critical gap for interaction prediction. ⚠️ FLAG.

---

## History

### Discovery and First Documentation

Clephedrone (4-CMC) was first described in the scientific literature by Taschwer et al. (2014 [Ref 17]) at Karl-Franzens-University Graz, who characterized a commercially available sample obtained from an online vendor (deboralabs.com). The substance had recently become available via the internet as a "research chemical." The study confirmed identity by GC-MS and NMR and established that the commercially available form was a **racemic mixture**.

First detection on the **European drug market** was in **June 2014**, per EMCDDA/EUDA monitoring data [web_retrieved — EUDA Early Warning System records]. This places clephedrone among the wave of para-halogenated cathinones that emerged following the scheduling of earlier cathinones (particularly mephedrone and flephedrone) in several European jurisdictions. Grifell et al. (2017 [Ref 11]) noted that 4-CMC appeared on markets where mephedrone had been controlled as a direct substitute product.

### Market Development

Majchrzak et al. (2018 [Ref 21]) reviewed cathinone derivatives appearing on the illegal drug market 2014–2017, identifying 4-CMC as part of a broader wave of ring-substituted methcathinone analogues designed to circumvent scheduling laws. By the mid-2020s, 4-CMC had become **one of the most frequently seized synthetic cathinones in Europe**, along with 3-CMC and 3-MMC (Berardinelli et al. 2024 [Ref 4]; Poyatos et al. 2025 [Ref 1]).

Spanish drug checking services identified clephedrone in **29 samples between 2014–2016**, often sold misrepresented as 3-MMC, MDMA, ketamine, or other cathinones [web_retrieved — EnergyControl data cited in Grifell 2017]. This mislabeling represents a substantial harm amplification risk.

### Regulatory History

| Date | Event |
|------|-------|
| June 2014 | First detected on European drug market |
| ~2014 | First published characterization (Taschwer et al.) |
| 2015 | Controlled in China |
| 2016 | Covered by UK Psychoactive Substances Act (blanket ban) |
| 2020 | Scheduled under UN 1971 Convention (Schedule II) |
| December 30, 2024 | US DEA proposed Schedule I placement |
| November 17, 2025 | US DEA final rule published |
| December 17, 2025 | US Schedule I effective date |

Germany controlled 4-CMC separately (specific date not confirmed in searches). Poland — which had high domestic seizure rates — reportedly lacked specific national scheduling until covered by the UN 2020 action [Tomczak et al. 2018 [Ref 10] note; Romańczuk et al. 2023 [Ref 18] context].

---

## Subjective Effects

### Human Data (Poyatos et al. 2025 [Ref 1])

The only published controlled human study (n=8, oral 100 or 150 mg, observational):
- Stimulant-like subjective effects observed over 5-hour monitoring period
- **Delayed onset and peak of effects** compared to methylone (150 or 200 mg oral)
- Cortisol elevation detected in oral fluid, indicating a biological stress/stimulant response
- The study design did not allow quantification of specific effect domains; subjective effects were assessed broadly as "stimulant-like"

⚠️ FLAG: The Poyatos et al. (2025) study was non-controlled, observational, used self-selected doses, and had a small sample (n=8, predominantly women). Specific VAS scores or questionnaire data are not reported in the available abstract.

### Animal and Structural Data

Wojcieszak et al. (2021 [Ref 9]) describe 4-CMC as producing **psychostimulant and empathogenic effects** by enhancing dopaminergic, noradrenergic, and serotonergic neurotransmission — consistent with its triple monoamine releasing mechanism. This pharmacological profile is similar to MDMA (empathogenic) and mephedrone, suggesting:
- Stimulant effects: energy, wakefulness, stimulation
- Mood elevation and euphoria
- Social facilitation and empathy enhancement
- Increased heart rate and blood pressure (subjectively perceived)

The balanced DAT/SERT activity suggests a more empathogenic character than purely DA-selective cathinones [Ref 27, Negus & Banks 2017], though less pronounced than MDMA given the modest DAT preference.

### Harm Reduction Source (web_retrieved — low confidence)

EduDrugs.org [Ref 29] reports the following subjective effects from user reports: increased energy, sociability, mood enhancement, stimulation, alertness, increased heart rate, euphoric feelings, and sometimes empathogenic feelings. These are consistent with the pharmacological profile but are not from controlled studies. Oral onset window recommended as 2+ hours before redosing; intranasal onset recommended at 30–90 minutes. These are user-report-only data; not confirmed in controlled studies.

### Effect Taxonomy Proposals

Based on documented pharmacology and available human/animal data, the following effect taxonomy entries are most strongly supported:

**Body:** stimulation, wakefulness, appetite-suppression, increased heart rate perception, bruxism, excessive sweating, pupil-dilation, vasoconstriction, temperature-dysregulation, dry-mouth, muscle-tension, restlessness, insomnia (at high doses)

**Thinking:** focus-enhancement, thought-acceleration, motivation-enhancement, compulsive-redosing-urge, analysis-enhancement

**Feeling:** euphoria, anxiety (particularly at high doses or comedown), emotional-enhancement, empathy-enhancement, irritability (comedown)

**Self:** sociability-enhancement, communication-enhancement, disinhibition

These are inferred from the MDMA-type pharmacological profile and limited human study data. ⚠️ FLAG: Only stimulant-like effects are confirmed in published controlled human data. Empathogenic/MDMA-like effects are pharmacologically plausible but not directly demonstrated in human studies.

---

## Dose & Duration Data

⚠️ These data are editorial estimates based on the evidence hierarchy described below. Flag for human editorial review.

### Evidence Base

Published human studies (Poyatos et al. 2025 [Ref 1]; Núñez-Montero et al. 2023 [Ref 6]; Massano et al. 2024 [Ref 5]) used **oral doses of 100–150 mg** as the administered range in self-selected volunteers. These were not dose-ranging studies — they do not define threshold, light, common, or heavy doses.

No published dose-ranging studies, LD50 data in humans, or formal dose-effect characterizations exist.

### Dose Proposals (Oral ROA — Analog Inference + Limited Human Data)

| Range | Proposed Dose | Basis |
|-------|--------------|-------|
| Threshold | ~25–50 mg | Structural analog inference (mephedrone comparison); below doses used in human studies |
| Light | ~50–100 mg | Lower bound of human study range |
| Common | ~100–150 mg | Doses used in human studies (Poyatos 2025 [Ref 1]) |
| Strong | ~150–200 mg | Upper bound of human study context + mephedrone analog |
| Heavy | >200 mg | Extrapolated; above studied range ⚠️ safety-critical |

⚠️ FLAG: All dose proposals for ranges outside 100–150 mg oral are structural analog inferences, NOT confirmed human data. Requires editorial review.

### Duration Proposals (Oral ROA)

| Phase | Estimated Duration | Basis |
|-------|-------------------|-------|
| Onset | 60–90 min | Delayed vs methylone; oral fluid peak ~3h (Núñez-Montero 2023 [Ref 6]) |
| Peak | 2–4 h | Oral fluid peak concentration window |
| Total effects | 4–6 h | Effects observable over 5h monitoring in Poyatos 2025 [Ref 1] |
| Aftereffects | 2–4 h | No published data; structural analog inference |

⚠️ FLAG: Duration estimates are based on pharmacokinetic proxy data (oral fluid concentration timing) and the monitoring window of the human study, not direct pharmacodynamic effect duration measurements.

---

## Safety & Toxicity

### In Silico Toxicity Predictions

Jurowski & Niżnik (2024 [Ref 3]) published the first in silico toxicity assessment of 4-CMC:
- **Acute toxicity (LD50):** Significant predicted acute toxicity with **species-specific variability** (specific predicted LD50 values are in the paper but not in the available abstract)
- **Genotoxicity:** Moderate genotoxic potential; risk of DNA damage
- **Cardiotoxicity:** Notable risk via **hERG channel inhibition** (predicted)
- **Endocrine disruption:** Low probability of estrogen receptor alpha (ERα) interaction; minimal estrogenic activity
- Bassi et al. (2025 [Ref 22]) independently predicted **drug-drug interaction potential and cardiotoxicity** for all CMC compounds including 4-CMC

⚠️ FLAG: All LD50 and genotoxicity data are in silico predictions only. No in vivo LD50 or genotoxicity data from animal or human studies are available.

### In Vitro Neurotoxicity

Zhou et al. (2020 [Ref 8]) found that 4-CMC is **cytotoxic** in SH-SY5Y human neuroblastoma cells (both undifferentiated and differentiated):
- **IC50 for ATP depletion:** ~1.4 mM (differentiated cells less sensitive)
- Decreased mitochondrial membrane potential
- Impaired electron transport chain function
- Increased reactive oxygen species (ROS)
- Induction of **apoptosis via the endogenous (mitochondrial) pathway**

Important limitation: cytotoxic concentrations (~1.4 mM) are substantially higher than plasma concentrations observed in living users (1.3–75.3 ng/mL = ~0.007–0.38 µM) and even in fatalities (56.2–1870 ng/mL = ~0.28–9.5 µM). The relevance of mitochondrial toxicity at pharmacological doses remains uncertain. However, para-chloro substitution specifically increased toxicity compared to unsubstituted methcathinone [Ref 8].

Wojcieszak et al. (2020 [Ref 7]) found that 4-CMC cytotoxicity in SH-SY5Y cells **emerged and intensified after prolonged incubation**, suggesting the mechanism is indirect and unrelated to acute monoamine transporter interactions. This may be relevant to chronic/repeated use toxicity.

### Blood Cell Membrane Effects

Trynda et al. (2026 [Ref 12; Ref 32]) demonstrated that clephedrone at concentrations of **170 ng/mL and 2700 ng/mL** (forensically relevant concentrations) alters the surface charge density of erythrocyte and platelet membranes measured by microelectrophoresis. Implications for coagulation or red blood cell function require further study.

### Forensic Blood Concentrations

Tomczak et al. (2018 [Ref 10]) reported the first validated GC-MS method for 4-CMC quantification in blood, applied to **15 forensic cases**:
- **Non-fatal intoxications** (including driving under the influence): 1.3–75.3 ng/mL
- **Fatalities** (overdose, suicide, traffic accidents): 56.2–1870 ng/mL

⚠️ FLAG: All fatalities involved 4-CMC in blood, but polydrug use was documented in many cases; 4-CMC alone as cause of death was not always established. Overlap between non-fatal and fatal ranges (both include concentrations around 56–75 ng/mL) precludes simple concentration-based lethality thresholds.

### Postmortem Case Series

Romańczuk et al. (2023 [Ref 18]) presented **27 CMC-related deaths** reported at the Department of Forensic Medicine in Kraków, Poland, between 2016–2022 (involved CMC isomers — primarily 3-CMC and/or 4-CMC). Key findings:
- CMC is a major toxicological opinion challenge in Poland
- Significant stability problems in postmortem biological material
- Dihydro-CMC (ketoreduced metabolite) detected in blood in every case, even when parent drug was absent
- Toxicity assessment and cause-of-death determination is difficult given unpredictable effects

### Fatal Polydrug Case

Nowak et al. (2021 [Ref 20]) reported a **fatal polydrug intoxication** (Poland, 2017) where 4-CMC was present alongside U-47700, N-ethylhexedrone, adinazolam, 4-CIC, and sertraline. Blood concentrations: 4-CMC = 1.7 ng/mL (low); U-47700 = 1470 ng/mL (high, consistent with lethal opioid toxicity). This case demonstrates 4-CMC use in high-risk polydrug contexts but 4-CMC was not the proximate cause of death.

### Non-Fatal Intoxication

Klavže et al. (2016 [Ref 14]) reported the first clinical identification of 4-CMC in Slovenia in a **38-year-old male** who presented to the emergency department after ingesting an unknown drug mixture (including AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP, and 4-CMC) in a suicide attempt. He became somnolent and unresponsive to painful stimuli. The multi-drug context prevents attribution of specific symptoms to 4-CMC.

---

## Harm Reduction

### Adulteration Risk

Drug checking data indicate that clephedrone has been sold **mislabeled** as 3-MMC, MDMA, ketamine, and other cathinones. EnergyControl (Spain) identified 4-CMC in 29 samples 2014–2016 that were sold as other substances [web_retrieved — Grifell et al. 2017 context, Ref 11]. This mislabeling is particularly dangerous when users calibrate doses expecting MDMA or a less potent substance.

**Testing recommendations:**
- Infrared or Raman spectrometry (definitive identification — recommended over colorimetric reagents)
- Colorimetric reagent tests (Marquis, Froehde, Simon's) may indicate cathinone presence but cannot reliably identify specific analogues or distinguish from 4-CMC vs mephedrone vs other cathinones
- Drug checking services (FTIR, GC-MS) are the gold standard

### Cardiovascular Risk

4-CMC produces cardiovascular stimulation (elevated BP and HR) comparable to mephedrone in animal models [Ref 2]. Predicted hERG inhibition [Ref 3] suggests potential QT interval effects. Individuals with pre-existing cardiovascular conditions, arrhythmias, or hypertension face elevated risk. Emergency warning signs: chest pain, irregular heartbeat, severe shortness of breath, fainting.

### Temperature Regulation

High-dose 4-CMC in rats caused transient hypothermia [Ref 2]; however, the monoamine-releasing mechanism and serotonin release may produce hyperthermia in humans in warm environments (consistent with other serotonin/dopamine releasers). Adequate hydration and temperature monitoring are standard harm reduction recommendations, though no 4-CMC-specific data exist.

### Interaction Risks

See Interactions section. Priority interactions:
1. MAOIs — risk of serotonin syndrome/hypertensive crisis
2. Other serotonergic agents (SSRIs, SNRIs, lithium) — additive serotonin effects
3. Other stimulants — additive cardiovascular and CNS stimulant burden
4. Opioids — the fatal case (Nowak 2021 [Ref 20]) involved opioid co-ingestion; polydrug use significantly elevates fatality risk

### Redosing Risk

4-CMC's low clearance and long half-life [Ref 19] mean that plasma concentrations from a first dose may be substantially elevated when a second dose is taken, increasing cardiovascular and toxic burden unpredictably. The compulsive redosing behavior observed with monoamine releasers (consistent with the pharmacological profile) combined with slow elimination creates risk for accumulation.

### Stability (Harm Reduction Context)

The compound is susceptible to degradation in solution and at elevated temperatures [Refs 25, 20]. Stored samples may have reduced potency or may produce degradation products of unknown pharmacology.

---

## Tolerance & Dependence

### Tolerance

No published human tolerance data. In animal models, Wojcieszak et al. (2021 [Ref 9]) found that **7-day intermittent 4-CMC treatment produced behavioral sensitization** (rather than tolerance) in DBA/2J mice — i.e., locomotor activity increased rather than decreased with repeated exposure. This is consistent with the behavior of other monoamine releasing agents. Sensitization typically reflects dopaminergic neuroadaptation and may predict escalating abuse.

Cross-tolerance with other monoamine releasers (mephedrone, MDMA, amphetamine) is pharmacologically expected based on shared mechanism but not directly published for 4-CMC.

### Dependence Liability

4-CMC produced **no conditioned place preference (CPP)** in DBA/2J mice at the doses tested [Ref 9] — contrasting with 4-MeO-PVP (a more DA-selective compound) which did produce CPP. This is notable: lack of CPP suggests lower rewarding properties in this specific mouse strain at tested doses. However, CPP in one mouse strain at one dose range is not definitive.

⚠️ FLAG: The absence of CPP in mice should not be interpreted as absence of abuse potential in humans. 4-CMC is classified as Schedule I by the DEA [Ref 23] based on high abuse potential and the fact that it is a known drug of abuse with multiple forensic cases.

The balanced DAT/SERT activity theoretically reduces abuse liability compared to purely dopamine-selective agents (Negus & Banks 2017 [Ref 27]); however, 4-CMC still significantly activates DAT (release EC50 = 91 nM) and has extensive real-world abuse evidence.

### Withdrawal

Wojcieszak et al. (2021 [Ref 9]) assessed withdrawal from 14-day intermittent 4-CMC treatment in mice using the tail suspension test, forced swim test, and sucrose preference test. **No significant withdrawal symptoms** were detected in these depression/anhedonia measures, and motor performance on rotarod was not impaired after cessation. No locomotor impairment was observed.

⚠️ FLAG: These animal data should be interpreted cautiously. The absence of measurable withdrawal in 14-day rodent models does not rule out psychological withdrawal (craving, dysphoria) in humans following heavy use, particularly given the serotonin-releasing mechanism which is associated with post-MDMA emotional dysphoria.

---

## Interactions

No published human pharmacokinetic drug interaction studies exist for 4-CMC. All interaction risk assessments are mechanism-based or class-extrapolated.

### Pharmacodynamic Interactions

**Monoamine oxidase inhibitors (MAOIs):** ⚠️ **Severe risk.** 4-CMC releases large amounts of serotonin, dopamine, and norepinephrine; concurrent MAOI use prevents their metabolism, risking **serotonin syndrome** and **hypertensive crisis**. Serotonin syndrome can be fatal. Contrucci et al. (2020 [Ref 26]) identified this as the primary high-risk interaction for synthetic cathinones.

**SSRIs/SNRIs:** Pharmacodynamic interaction — SSRIs may blunt the serotonin-mediated subjective effects of 4-CMC by competing for SERT, while also increasing serotonergic tone, potentially increasing serotonin syndrome risk with high doses. A clinical case (Nowak 2021 [Ref 20]) documented sertraline co-administration with 4-CMC in a fatal polydrug case.

**Other stimulants (amphetamines, cocaine, other cathinones, MDMA):** Additive cardiovascular effects (BP, HR). Polydrug cathinone use was documented in the Romańczuk postmortem series [Ref 18].

**Opioids:** While not a direct pharmacodynamic interaction with 4-CMC's mechanism, the fatal case (Nowak 2021 [Ref 20]) involved U-47700 (a synthetic opioid), demonstrating the extreme fatality risk of cathinone/opioid polydrug combinations.

**Lithium:** Increased seizure risk with serotonin-releasing agents; combination generally contraindicated.

**Antihypertensives:** 4-CMC's robust cardiovascular stimulation (α1-mediated hypertension) may overcome antihypertensive medications and cause unpredictable BP effects.

### Pharmacokinetic Interactions

No published data on CYP enzyme inhibition or induction by 4-CMC. Given its low clearance classification [Ref 19], CYP inhibitors that further reduce 4-CMC clearance could significantly increase plasma concentrations. ⚠️ FLAG: CYP enzyme profile of 4-CMC is unknown — this is a critical interaction gap.

---

## Legal Status

| Jurisdiction | Status | Date | Reference |
|---|---|---|---|
| International (UN 1971 Convention) | Schedule II | 2020 | [Ref 24] |
| United States | Schedule I (CSA) | Effective December 17, 2025 | [Ref 23] |
| United Kingdom | Controlled (Psychoactive Substances Act 2016 blanket ban) | May 26, 2016 | [web_retrieved] |
| European Union | International control (UN 2020) | 2020 | [Ref 24] |
| Germany | Controlled substance | Specific date not confirmed | [web_retrieved] |
| China | Controlled | October 2015 | [web_retrieved] |
| Australia | Narcotic (requires import/export permits) | Date not confirmed | [web_retrieved — ODC] |
| Canada | Status not confirmed | — | ⚠️ FLAG: Unable to confirm from searches |
| Poland | Was unscheduled until UN 2020 scheduling | 2020 | [Ref 10, 18 context] |

**US Scheduling note:** The DEA NPRM was published December 30, 2024. No hearing requests were received. One anonymous comment opposed scheduling citing uninvestigated medical potential. The final rule was published November 17, 2025 (Federal Register Volume 90, Issue 219, pp. 51102–51105). Basis: high abuse potential, no currently accepted medical use, lack of accepted safety under medical supervision [Ref 23].

---

## Clinical Trials

**None found.** A search of ClinicalTrials.gov for "clephedrone" and "4-CMC synthetic cathinone" returned zero registered trials. No New Drug Application has been filed with the FDA. No evidence of clinical development for any therapeutic indication.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. This section is not applicable for this research cycle.

---

## Gaps & Flags

The following items require editorial attention or are safety-critical:

### Safety-Critical Gaps

1. ⚠️ **LD50 in vivo data:** No animal or human LD50 data. Only in silico predictions (Jurowski 2024 [Ref 3]). Do not use predicted LD50 values as if they were experimental.

2. ⚠️ **Dose threshold (light/heavy):** Only 100–150 mg oral range studied in humans. Proposed light and heavy dose boundaries are analog inferences only. All dose values outside 100–150 mg oral require editorial review before publication.

3. ⚠️ **Duration data:** Effect duration is estimated from pharmacokinetic proxy data (oral fluid peak timing), not direct pharmacodynamic measurement. Actual duration may differ significantly.

4. ⚠️ **CYP enzyme profile:** Unknown. Cannot predict pharmacokinetic drug interactions. This is a critical gap for interaction severity assessments.

5. ⚠️ **hERG inhibition:** Predicted computationally [Ref 3, 22], not confirmed in vitro or in vivo. Treat as a risk signal warranting cardiovascular caution, not an established fact.

6. ⚠️ **Fatality attribution:** All published fatalities involving 4-CMC are polydrug cases. No clean 4-CMC monocause fatality confirmed in published literature. The forensic blood concentration overlap between non-fatal and fatal ranges means no concentration threshold for lethality can be established.

### Data Absence Flags

7. **Active stereoisomer:** Not identified. Sold and used as racemate. Differential enantiomeric pharmacology unknown.

8. **Bioavailability:** Not published for any ROA.

9. **Human half-life (t½), Cmax, Tmax, Vd:** Not formally published; only inferred from oral fluid concentration timing.

10. **Intranasal pharmacokinetics:** 4-CMC intranasal PK not directly studied. Massano 2024 [Ref 5] and Núñez-Montero 2023 [Ref 6] administered 4-CMC orally and other cathinones intranasally — not 4-CMC intranasally.

11. **Receptor binding data beyond transporters:** No published Ki values for 5-HT2A, D1, D2, α1, β1, or other receptors.

12. **Tolerance kinetics in humans:** No published data.

13. **Canada legal status:** Not confirmed from available sources.

14. **First market appearance:** June 2014 is sourced from EMCDDA Early Warning System data but is web_retrieved (not an API-verified academic citation).

15. **Synthesis route:** No peer-reviewed synthesis paper for 4-CMC. The general chloromethcathinone synthesis route is described in multiple sources but no primary literature synthesis paper is indexed.

16. **Citation Registry Note:** Ref 16 in the citation registry is a duplicate of Ref 10 (same paper, Tomczak et al. 2018) due to a data entry error. The generation agent should treat Ref 10 as the canonical entry for this paper.